Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
复制标题
DOI：
10.1016/s0195-668x(03)00468-8
复制
发表时间：
2004-01-01
影响因子：
39.3
通讯作者：
Rupp, M
中科院分区：
文献类型：
--
作者：
Hanefeld, M;Cagatay, M;Rupp, M
目的：为了评估是否与α-葡萄糖苷酶抑制剂阿卡波糖治疗可以减少2型糖尿病patients.Methods和结果的心血管事件：此荟萃分析包括7个随机，双盲，安慰剂对照阿卡波糖的研究，最低治疗持续时间为52周。安全性有效的2型糖尿病患者被随机分配至阿卡波糖组（n= 1248）或安慰剂组（n=932）。主要结局指标是发生心血管事件的时间。采用考克斯回归分析进行主要分析。还研究了阿卡波糖对代谢参数的影响。阿卡波糖治疗显示出所有选定心血管事件类别风险降低的有利趋势。该治疗显著降低了“心肌梗死”的风险（风险比=0。36 [95% CI 0.16-0.80]，P=0.0120）和“任何心血管事件”（0.65 [95% CI 0.48-0.88]，P=0.0061）。血糖控制，甘油三酯水平，体重和收缩压也显着改善阿卡波糖treatment.Conclusion：阿卡波糖干预可以预防心肌梗死和心血管疾病的2型糖尿病患者白色他们中的大多数已经在密集的伴随心血管药物。(C)2003年由Elsevier Ltd代表欧洲心脏病学会出版。
Aims: To assess if treatment with the alpha-glucosidase inhibitor acarbose can reduce cardiovascular events in type 2 diabetic patients.Methods and results: This meta-anatysis included seven randomized, double-blind, placebo-controlled acarbose studies with a minimum treatment duration of 52 weeks. Type 2 diabetic patients valid for safety were randomized to either acarbose (n=1 248) or placebo (n=932). The primary outcome measure was the time to develop a cardiovascular event. Primary analysis was conducted using Cox regression analysis. The effect of acarbose on metabolic parameters was also investigated. Acarbose therapy showed favourable trends towards risk reduction for all selected cardiovascular event categories. The treatment significantly reduced the risk for 'myocardial infarction' (hazards ratio=0. 36 [95% Cl 0.16-0.80], P=0.0120) and 'any cardiovascular event' (0.65 [95% Cl 0.48-0.88], P=0.0061). Glycaemic control, triglyceride levels, body weight and systolic blood pressure also improved significantly during acarbose treatment.Conclusion: Intervention with acarbose can prevent myocardial infarction and cardiovascular disease in type 2 diabetic patients white most of them are already on intensive concomitant cardiovascular medication. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.